Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance
V. Thatikonda, H. Lu, S. Jurado, K. Kostyrko, C. A. Bristow, K. Bosch, N. Feng, S. Gao, D. Gerlach, M. Gerlach, S. Lieb, A. Jeschko, A. A. Machado, E. D. Marszalek, M. Mahendra, , M. H. Hofmann
This study shows that combining KRASG12C and SOS1 inhibitors improves anti-tumor response and delays resistance in KRASG12C-driven cancers.
bioRxiv · Jan 23, 2023Cancer Biology